Major Histocompatibility Complex Class II+Invariant Chain Negative Breast Cancer Cells Present Unique Peptides that Activate Tumor-specific T Cells from Breast Cancer Patients

Absence of Class II-Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells

(2011) M. M. van Luijn et al.   CANCER RESEARCH

Uncovering the Role of Invariant Chain in Controlling MHC Class II Antigen Capture

(2011) R. N. Germain   JOURNAL OF IMMUNOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Mass spectrometry in high-throughput proteomics: ready for the big time

(2010) Tommy Nilsson et al.   NATURE METHODS

A guided tour of the Trans-Proteomic Pipeline

(2010) Eric W. Deutsch et al.   PROTEOMICS

Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells

(2009) Jacobus J. Bosch et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

(2009) M. M. van Luijn et al.   HAEMATOLOGICA

Autophagy and Its Role in MHC-Mediated Antigen Presentation

(2009) V. L. Crotzer et al.   JOURNAL OF IMMUNOLOGY

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

(2009) F. R. Depontieu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

(2008) Minu K. Srivastava et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MHC class II transport at a glance

(2008) A. C. Berger et al.   JOURNAL OF CELL SCIENCE

Immunotherapy for Advanced Melanoma

(2008) Lei Fang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY